Topoisomerase II poisoning by ICRF-193.
K C Huang, H Gao, E F Yamasaki, D R Grabowski, S Liu, L L Shen, K K Chan, R Ganapathi, R M Snapka
Index: J. Biol. Chem. 276 , 44488-44494, (2001)
Full Text: HTML
Abstract
Antineoplastic bis(dioxopiperazine)s, such as meso-2,3-bis(2,6-dioxopiperazin-4-yl)butane (ICRF-193), are widely believed to be only catalytic inhibitors of topoisomerase II. However, topoisomerase inhibitors have little or no antineoplastic activity unless they are topoisomerase poisons, a special subclass of topoisomerase-targeting drugs that stabilize topoisomerase-DNA strand passing intermediates and thus cause the topoisomerase to become a cytotoxic DNA-damaging agent. Here we report that ICRF-193 is a very significant topoisomerase II poison. Detection of topoisomerase II poisoning by ICRF-193 required the use of a chaotropic protein denaturant in the topoisomerase poisoning assays. ICRF-193 caused dose-dependent cross-linking of human topoisomerase IIbeta to DNA and stimulated topoisomerase IIbeta-mediated DNA cleavage at specific sites on (32)P-end-labeled DNA. Human topoisomerase IIalpha-mediated DNA cleavage was stimulated to a lesser extent by ICRF-193. In vivo experiments with MCF-7 cells also showed the requirement of a chaotropic protein denaturant in the assays and selectivity for the beta-isozyme of human topoisomerase II. Studies with two topoisomerase IIbeta-negative cell model systems confirmed significant topoisomerase II poisoning by ICRF-193 in the wild type cells and were consistent with beta-isozyme selectivity. Common use of only the detergent, SDS, in assays may have led to failure to detect topoisomerase II poisoning by ICRF-193 in earlier studies.
Related Compounds
Related Articles:
2003-09-29
[Mutat. Res. 530 , 35-46, (2003)]
1999-05-15
[Biochem. Pharmacol. 57 , 1105, (1999)]
2002-09-27
[J. Biol. Chem. 277 , 36832, (2002)]
2001-03-01
[Mol. Pharmacol. 59 , 453, (2001)]